JPMorgan Becomes Successor Depositary Bank For ADR Program Of Roche

JPMorgan has been appointed as the successor depositary bank for the American Depositary Receipt (ADR) program of Roche Holding Ltd (Roche), research focused healthcare group in the fields of pharmaceuticals and diagnostics. Roche's ADR (RHHBY), a program on OTCQX, is

By None

JPMorgan has been appointed as the successor depositary bank for the American Depositary Receipt (ADR) program of Roche Holding Ltd (Roche), research-focused healthcare group in the fields of pharmaceuticals and diagnostics. Roche’s ADR (RHHBY), a program on OTCQX, is also one of the top-five OTC ADR programs in Western Europe by value, and is among the most actively traded with $4.9 billion in depositary receipts (DRs) traded annually.

Roche joins a strong list of major European pharmaceutical firms for which JPMorgan acts as ADR depositary including: AstraZeneca plc, Novartis AG, sanofi-aventis, and Shire plc.

“We are proud to have Roche, a renowned pharmaceutical company, join our roster of clients. We look forward to working with the company to help it benefit from US demand for foreign equities,” says Claudine Gallagher, global head of Depositary Receipts at JPMorgan.

JPMorgan created the first-ever DR in 1927 for British retailer Selfridges. Today the overall DR market comprises more than 1,800 companies from over 75 countries in the form of American Depositary Receipts (ADRs) or Global Depositary Receipts (GDRs).

For market information on DRs and international equities go to JPMorgan’s award-winning Web site www.adr.com.

For more information on JPMorgan’s DR services go to http://www.jpmorgan.com/visit/adr.

D.C.

«